Top Stories
-
The Food and Drug Administration on Thursday overcame doubts from agency scientists and approved a fiercely debated drug for ALS
-
Jinsy Andrews, an associate professor in the Department of Neurology at the Vagelos College of Physicians and Surgeons, speaks about the big difference between Aduhelm and AMX0035.
-
A new initiative led by Columbia University and the n-Lorem Foundation will develop personalized therapies for individuals with "nano-rare" genetic forms of ALS and treat them for free, for life.
Topic
-
An experimental drug first tried at Columbia University Irving Medical Center as a last-ditch effort to help a 25-year-old woman with juvenile ALS is now being tested in ALS patients
Latest News
- October 19, 2021
Announcing The Project ALS Research Advisory Board
- October 5, 2021
Six Columbia University scientists have received NIH High-Risk, High-Reward grants that are given to exceptionally creative scientists proposing unconventional, but potentially high-impact, research
- June 13, 2021
A public battle rages over access to experimental, trial-phase drugs
Topic
- June 2, 2021
Lou Gehrig’s worst full season was his best as amyotrophic lateral sclerosis, or ALS, was beginning to erode him from the inside.
Topic
-
Source:
BLOOMBERG NEWSApril 6, 2021Neil Shneider, Stockman-Mauriello’s doctor and director of the Eleanor and Lou Gehrig ALS Center at Columbia University in New York, nonetheless asked Biogen for access.
-
Source:
The Wall Street JournalSeptember 2, 2020“Anything that can slow down the rate of decline in a disease that has no cure—or no treatment to reverse symptoms—is good,” said Jinsy Andrews.
Topic
-
Source:
The New York TimesSeptember 2, 2020“This is very encouraging,” said Dr. Neil Shneider, director of the Eleanor and Lou Gehrig A.L.S. Center at Columbia University, who was not involved.
Topic
-
Jinsy Andrews, MD, MSc, FAAN has been elected co-chair of the Northeast ALS Consortium (NEALS) for a four-year term.
Topic
